Giant gastrointestinal stromal tumour of rare sarcomatoid epithelioid subtype: case study and literature review.

World J Gastroenterol

Gustaw Lech, Tomasz Guzel, Ireneusz Wojciech Krasnodębski, Department of General, Gastroenterological and Oncological Surgery, Medical University of Warsaw, 02091 Warsaw, Poland.

Published: March 2015

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract, but they represent less than 3% of all gastrointestinal tract malignancies. This is a detailed case study of a 52-year-old male patient treated for very uncommon histological subtype of gastric GIST with atypical clinical presentation, asymptomatic progress and late diagnosis. The resected tumour, giant in diameters, was confirmed to represent the most rare histopathologic subtype of GISTs - sarcomatoid epithelioid GIST. We report this case and review the literature with a special focus on pathomorphological evaluation, biological aggressiveness and prognostic factors. To our knowledge this is the first report of giant GIST of very uncommon sarcomatoid epithelioid subtype. It is concluded that clinicians should pay attention to the fact that initial diagnosis may be delayed due to mildly asymptomatic and non-specific clinical presentation. Asymptomatic tumours diagnosed at a late stage, which is often the case, can be large on presentation. Prognosis for patients diagnosed with GIST depend on tumour size, mitotic rate, histopathologic subtype and tumour location. That is why early diagnosis and R0 resection, which is usually feasible and safe even in giant gastric sarcomatoid epithelioid subtype of GISTs, are the key factors for further treatment and good prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363772PMC
http://dx.doi.org/10.3748/wjg.v21.i11.3388DOI Listing

Publication Analysis

Top Keywords

sarcomatoid epithelioid
16
epithelioid subtype
12
gastrointestinal stromal
8
case study
8
gastrointestinal tract
8
clinical presentation
8
presentation asymptomatic
8
histopathologic subtype
8
subtype gists
8
subtype
6

Similar Publications

Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA.

ESMO Open

January 2025

Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pulmonary Medicine, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:

Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic therapy. Since 2022, nivolumab-ipilimumab (nivo/ipi) has replaced chemotherapy as the standard first-line treatment for dPM in the Netherlands. Chemotherapy remains a rational second-line treatment.

View Article and Find Full Text PDF

Current drug therapy for pleural mesothelioma.

Respir Investig

January 2025

Department of Respiratory Medicine, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, 350-1298, Japan. Electronic address:

Pleural mesothelioma (PM) is a rare and highly aggressive malignancy originating from the pleural lining, with a median overall survival of merely 1 year. This cancer primarily arises from mesothelial cells following exposure to carcinogenic, biopersistent mineral fibers, particularly asbestos. The histological subtypes of mesothelioma are epithelioid (approximately 60%), sarcomatoid (20%), and biphasic (20%), exhibiting epithelioid and sarcomatoid characteristics.

View Article and Find Full Text PDF

Recurrence Patterns and Management after Pleurectomy Decortication for Pleural Mesothelioma.

Ann Surg

January 2025

The Thoracic Surgery Oncology laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham, and Women's Hospital, and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Objective: We hypothesize that recurrence following pleurectomy decortication (PD) is primarily local. We explored factors associated with tumor recurrence patterns, disease-free interval (DFI), and post-recurrence survival (PRS).

Summary Background Data: Tumor recurrence is a major barrier for long-term survival after pleural mesothelioma (PM) surgery.

View Article and Find Full Text PDF

Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.

Mod Pathol

January 2025

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA. Electronic address:

Histologic features, including architectural patterns, cytologic features, and 2021 World Health Organization nuclear grade have been shown to have prognostic significance in epithelioid diffuse pleural mesothelioma (DPM). Biphasic and sarcomatoid DPM, regardless of morphology, have worse outcomes. These prognostic findings are well-established but correlation of architectural patterns, cytologic features, and nuclear grade with genetic alterations has not been well studied.

View Article and Find Full Text PDF

Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor (ICI), for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM) based on the MERIT trial, a phase II study of 34 cases. However, concerns regarding limited evidence persist.

Methods: We retrospectively analyzed 83 patients with previously treated, unresectable, advanced, or recurrent malignant pleural mesothelioma (MPM) treated with nivolumab from August 2018 to May 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!